Neuphoria Therapeutics (Nasdaq: NEUP) will receive a $15 million milestone payment from Merck due to the initiation of a Phase 2 clinical trial for MK-1167. MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator, targets the symptoms of Alzheimer’s disease dementia. This marks the second milestone payment in their collaboration.
This Phase 2 trial initiation is a crucial step forward for Alzheimer’s diseaseAlzheimer’s disease research and treatment. It signifies a validation of the potential of α7 nicotinic acetylcholine receptor targeted therapeutics, a mechanism of action that holds promise for addressing cognitive decline in Alzheimer’s. The initiation of a major pharmaceutical company like Merck sponsoring the Phase 2 trial demonstrates confidence in the approach and adds significant resources to its development, increasing the likelihood of advancing a viable treatment option for this devastating disease. This progress offers hope for patients and their families, as current treatments offer limited efficacy.
This $15 million payment is part of a larger agreement between Neuphoria and Merck, under which Neuphoria could receive up to $450 million in future milestone payments and royalties on net sales. This financial boost reinforces Neuphoria’s financial stability and supports their continued research and development efforts, including their lead drug candidate BNC210 for social anxiety disorder and PTSD.
The initiation of this Phase 2 trial represents a significant step towards potentially providing a new treatment option for Alzheimer’s disease. The progress achieved validates Neuphoria’s platform and strengthens their partnership with Merck. The successful completion of this trial could lead to further advancements in the development of MK-1167 and ultimately benefit patients suffering from Alzheimer’s. This success also reinforces the potential of Neuphoria’s ion channel targeting platform for developing treatments for other neuropsychiatric disorders.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
